


MICs of isoniazid, rifampin may predict tuberculosis relapse

August 30 2018



(HealthDay)—In pretreatment isolates of *Mycobacterium tuberculosis*,

higher minimum inhibitory concentrations (MICs) of isoniazid and rifampin below the standard resistance breakpoint are associated with increased risk of relapse, according to a study published in the Aug. 30 issue of the *New England Journal of Medicine*.

Roberto Colangeli, Ph.D., from the Rutgers-New Jersey Medical School in Newark, and colleagues analyzed pretreatment isolates of *M. tuberculosis* from patients who subsequently had a relapse or were cured to determine the MIC values of isoniazid and rifampin that were below the standard resistance breakpoint. This analysis was combined with clinical, radiologic, and laboratory data to generate predictive relapse models, which were then validated.

The researchers found that the mean MIC of isoniazid below the breakpoint was 0.0334 ± 0.0085 $\mu\text{g/mL}$ and 0.0286 ± 0.0092 $\mu\text{g/mL}$ in the relapse and cure groups, respectively. This represented a 1.17-fold higher value in the relapse group. For rifampin, the corresponding MIC values were 0.0695 ± 0.0276 $\mu\text{g/mL}$ and 0.0453 ± 0.0223 $\mu\text{g/mL}$, representing a 1.53-fold higher value in the relapse group. In a multivariable analysis, higher MIC values remained associated with relapse. The area under the curve was 0.779 in an [analysis](#) of receiver-operating-characteristic curves of relapse based on these MIC values.

"Higher pretreatment MIC values for either isoniazid or [rifampin](#) were associated with an increased risk of relapse, even after accounting for other potential risk factors for [relapse](#)," write the authors of an accompanying editorial.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

[Editorial \(subscription or payment may be required\)](#)

Copyright © 2018 [HealthDay](#). All rights reserved.

Citation: MICs of isoniazid, rifampin may predict tuberculosis relapse (2018, August 30)
retrieved 12 May 2023 from <https://medicalxpress.com/news/2018-08-mics-isoniazid-rifampin-tuberculosis-relapse.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.